Quality improvement and tissue-type plasminogen activator for acute ischemic stroke a cleveland update

Stroke

Volumn 34, Issue 3, 2003, Pages 799-800

  Katzan, Irene L ^a,b   Hammer, Maxim D ^a   Furlan, Anthony J ^a   Hixson, Eric D ^a   Nadzam, Deborah M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Cerebral infarction; Quality of health care; Thrombolytic therapy

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; HUMAN; PRIORITY JOURNAL; QUALITY CONTROL; RETROSPECTIVE STUDY; SYMPTOMATOLOGY; TREATMENT OUTCOME; UNITED STATES;

ACUTE DISEASE; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOLS; DRUG UTILIZATION REVIEW; HUMANS; INFUSIONS, INTRAVENOUS; MEDICAL AUDIT; MULTI-INSTITUTIONAL SYSTEMS; OHIO; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF HEALTH CARE; RETROSPECTIVE STUDIES; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TOTAL QUALITY MANAGEMENT;

EID: 0037338484     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000056944.42686.1E     Document Type: Article

References (11)

1. Lenzer J. Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign. BMJ. 2002;324:723-729.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
3. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283:1145-1150.
4. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, Sila CA. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA. 2000;283:1151-1158.
5. Hoffman J. IV t-PA interventional therapy for acute stroke patients: negative position. Stroke Interventionalist. 2002;11:6-10.
6. Katzan IL, Furlan AJ, Hammer MD, Saneto R, Mikesell T, Waggoner M, Sila CA. Retrospective assessment of five stroke scales and disability indexes in the community setting. Stroke. 2000;31:321. Abstract.
7. Adams HP Jr, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Kwiatkowski T, Lyden PD, Marler JR, Torner J, Feinberg W, Mayberg M, Thies WL. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. Stroke. 1996;27:1711-1718.
8. Tanne D, Bates VE, Verro P, Kasner SE, Binder JR, Patel SC, Mansbach HH, Daley S, Schultz LR, Karanjia PN, et al. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey: the t-PA Stroke Survey Group. Neurology. 1999;53:424-427.
9. Grotta JC, Burgin WS, El Mitwalli A, Long M, Campbell M, Morgenstem LB, Malkoff M, Alexandrov AV. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol. 2001;58:2009-2013.
10. Hlatky MA, Cotugno H, O'Connor C, Mark DB, Pryor DB, Califf RM. Adoption of thrombolytic therapy in the management of acute myocardial infarction. Am J Cardiol. 1988;61:510-514.
11. Krall SP, Reese CL, Donahue L. Effect of continuous quality improvement methods on reducing triage to thrombolytic interval for acute myocardial infarction. Acad Emerg Med. 1995;2:603-609.